Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 11:16:1617906.
doi: 10.3389/fimmu.2025.1617906. eCollection 2025.

Multiplex imaging analysis of the tumor immune microenvironment for guiding precision immunotherapy

Affiliations
Review

Multiplex imaging analysis of the tumor immune microenvironment for guiding precision immunotherapy

Feng Liu et al. Front Immunol. .

Abstract

Cutting-edge multiplex imaging technologies have significantly advanced our understanding of the tumor immune microenvironment (TIME), delivering nanometer-scale spatial resolution that illuminates previously inaccessible cellular interactions and organizational patterns. This mini-review discusses the latest multiplex imaging methods, including Imaging Mass Cytometry (IMC), Multiplexed Ion Beam Imaging (MIBI), Cyclic Immunofluorescence (CycIF), and Digital Spatial Profiling (DSP), emphasizing their roles in identifying spatial immune signatures predictive of immunotherapy responses. Clinical applications across various cancers-such as NSCLC, melanoma, breast cancer, colorectal cancer, and hepatocellular carcinoma-highlight how spatially resolved immune profiles can enhance patient stratification and treatment personalization. Notably, increased CD8+ T cell density and spatial colocalization with tumor cells have been broadly correlated with improved immunotherapy response and survival across multiple cancer types. Despite current technical and analytical challenges, ongoing technological advancements and integration with emerging methods like spatial transcriptomics and super-resolution imaging promise broader clinical utility, ultimately improving patient outcomes in precision immunotherapy.

Keywords: immune cell interactions; immunotherapy biomarkers; multiplex imaging; spatial profiling; tumor immune microenvironment (TIME).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic overview of multiplex imaging platforms used to analyze spatial protein expression in the TIME. (a) IMC and MIBI platforms utilize metal-conjugated antibodies detected by mass spectrometry, enabling highly multiplexed analyses with minimal spectral overlap. (b) Cyclic fluorescence-based imaging techniques such as CycIF and multiplex IHC rely on sequential antibody staining and stripping cycles, providing moderate multiplexing with broad accessibility. (c) Oligonucleotide-based imaging methods including CODEX and SABER use DNA-barcoded antibodies for high-plex fluorescence detection with spatial precision.

References

    1. Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T cell receptor خ٢ -chain constant region for immunotherapy of T cell Malignancies. Nat Med. (2017) 23:1416–23. doi: 10.1038/nm.4444, PMID: - DOI - PubMed
    1. Gao Y, He J, Wang J, Xu H, Ma L. Chimeric antigen receptor T cell immunotherapy for gynecological Malignancies. Crit Rev Oncology/Hematology. (2025) 209:104680. doi: 10.1016/j.critrevonc.2025.104680, PMID: - DOI - PubMed
    1. Yu L, Lanqing G, Huang Z, Xin X, Minglin L, Fa-hui L, et al. T cell immunotherapy for cervical cancer: challenges and opportunities. Front Immunol. (2023) 14:1105265. doi: 10.3389/fimmu.2023.1105265, PMID: - DOI - PMC - PubMed
    1. Xu Y, Liu Y, Ge Y, Li H, Zhang Y, Wang L. Drug resistance mechanism and reversal strategy in lung cancer immunotherapy. Front Pharmacol. (2023) 14:1230824. doi: 10.3389/fphar.2023.1230824, PMID: - DOI - PMC - PubMed
    1. Wang M, Yu F, Li P. Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications. Front Immunol. (2023) 14:1268745. doi: 10.3389/fimmu.2023.1268745, PMID: - DOI - PMC - PubMed